<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

| Antibodies | Yes (indicate where provided: section/paragraph) | n/a |
|--|--|-----|
| For commercial reagents, provide supplier | No antibodies used | × |
| name, catalogue number and RRID, if available. | | |

| Cell materials | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|-----|
| Cell lines: Provide species information, strain. | No cell lines used | × |
| Provide accession number in repository OR | | |
| supplier name, catalog number, clone number, | | |
| OR RRID | | |
| Primary cultures: Provide species, strain, sex of | No cultures used | × |
| origin, genetic modification status. | | |

| Experimental animals | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|-----|
| Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID | No Laboratory animals used | × |
| Animal observed in or captured from the field: Provide species, sex and age where possible | No Laboratory animals used | × |
| Model organisms: Provide Accession number in repository (where relevant) OR RRID | No model organisms used | × |

| Plants and microbes | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|-----|
| Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens) | No plants used | × |
| Microbes: provide species and strain, unique accession number if available, and source | No microbes used | × |

| Human research participants | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|-----|
| Identify authority granting ethics approval (IRB or | Ethics Committee of the Ninth People's Hospital of | |
| equivalent committee(s), provide reference number | Shanghai Jiaotong University School of Medicine [No. 89 | |
| for approval. | (2012) 21] (Page 3 line 14-16) | |
| | Section: Materials and Methods | |
| Provide statement confirming informed consent | Ethics Committee of the Ninth People's Hospital of | |
| obtained from study participants. | Shanghai Jiaotong University School of Medicine [No. 89 | |
| | (2012) 21] (Page 3 line 14-16) | |
| | Section: Materials and Methods | |
| Report on age and sex for all study participants. | Table 1 | |

Design

| Study protocol | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|-----|
| For clinical trials, provide the trial registration | No trial | × |
| number OR cite DOI in manuscript. | | |

| Laboratory protocol | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|-----|
| Provide DOI or other citation details if detailed step- | No laboratory investigation | × |
| by-step protocols are available. | | |

| Experimental study design (statistics details) | Yes (indicate where provided: section/paragraph) | n/a |
|--|--|-----|
| State whether and how the following have been | No experimental study | × |
| done, or if they were not carried out. | | |
| Sample size determination | No experimental study | × |
| Randomisation | No experimental study | × |
| Blinding | No experimental study | × |
| Inclusion/exclusion criteria | No experimental study | × |

| Sample definition and in-laboratory replication | Yes (indicate where provided: section/paragraph) | n/a |
|--|--|-----|
| State number of times the experiment was | Section: Materials and Methods | |
| replicated in laboratory | Page 4, line 1-9 | |
| Define whether data describe technical or biological | Section: Materials and Methods | |
| replicates | Page 4, line 1-9 | |

| Ethics | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|-----|
| Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | Ethics Committee of the Ninth People's Hospital of Shanghai Jiaotong University School of Medicine [No. 89 (2012) 21] (Page 3 line 14-16) Section: Materials and Methods | |
| Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | No animals studied | × |
| Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why. | No field samples | × |

| Dual Use Research of Concern (DURC) | Yes (indicate where provided: section/paragraph) | n/a | i |
|--|--|-----|---|
| If study is subject to dual use research of concern, | No dual use research | × | i |
| state the authority granting approval and reference | | | i |
| number for the regulatory approval | | | ì |

Analysis

| Attrition | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|-----|
| State if sample or data point from the analysis is | No data excluded | × |
| excluded, and whether the criteria for exclusion were | | |
| determined and specified in advance. | | |

| Statistics | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|-----|
| Describe statistical tests used and justify choice of | Section: Materials and Methods, Statistical analysis | |
| tests. | Page 4, line 19-22 | |

| Data Availability | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|-----|
| State whether newly created datasets are available, | Section: Results, Expression profile and characteristics of | |
| including protocols for access or restriction on | differentially expressed circRNAs between OLP and | |
| access. | normal oral mucosal, paragraph 2 | |
| If data are publicly available, provide accession | GSE131567 | |
| number in repository or DOI or URL. | Section: Results, Expression profile and characteristics of | |
| If publicly available data are reused, provide | Data available through Freedom of Information request | × |
| accession number in repository or DOI or URL, where | | |
| possible. | | |

| Code Availability | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|-----|
| For all newly generated code and software essential | No new code or software used | × |
| for replicating the main findings of the study: | | |
| State whether the code or software is available. | No new code or software used | × |
| If code is publicly available, provide accession | No new code or software used | × |
| number in repository, or DOI or URL. | | |

Reporting

| Adherence to community standards | Yes (indicate where provided: section/paragraph) | n/a |
|--|---|-----|
| MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR. | Journal style followed | n/a |
| State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript. | ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication. (In introduction and footnote section, page 3, line 1-2, and page 10, line 1-2) | |

Article information: http://dx.doi.org/10.21037/apm-20-2253